Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 6/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027703 | 0.80 | CYP2C19 (0.61) | CYP2C19RAB9ACTSCSLC1A3SLC1A2 | |
| SCHEMBL288287 | 0.80 | CYP2C19 (0.61) | CYP2C19RAB9ACTSCSLC1A3SLC1A2 | |
| SCHEMBL2027702 | 0.80 | CYP2C19 (0.61) | CYP2C19RAB9ACTSCSLC1A3SLC1A2 | |
| SCHEMBL17009212 | 0.78 | CYP2C19 (0.58) | CYP2C19RAB9ACTSCSLC1A3SLC1A2 | |
| SCHEMBL5724646 | 0.78 | CYP2C19 (0.62) | CYP2C19RAB9ACTSCSLC1A3SLC1A2 | |
| SCHEMBL6533655 | 0.77 | CYP2C19 (0.66) | CYP2C19RAB9ACTSCSLC1A3SLC1A2 | |
| SCHEMBL29065802 | 0.77 | CYP2C19 (0.61) | CYP2C19RAB9ACTSCPOLBTDP1 | |
| SCHEMBL28814778 | 0.77 | CYP2C19 (0.61) | CYP2C19RAB9ACTSCPOLBTDP1 | |
| SCHEMBL29065811 | 0.77 | CYP2C19 (0.61) | CYP2C19RAB9ACTSCPOLBTDP1 | |
| SCHEMBL355063 | 0.76 | CYP2C19 (0.47) | CYP2C19RAB9ACTSCSLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185524-B1 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER LAMBERT CO (US) | 2005-01-26 | — | — | EP | claimed |
| US-6833385-B2 | Thiophene derivatives; epilepsy, faintness attacks, depression, anxiety, panic, pain; neurodegenerative, neuropathological and gastrointestinal disorders | WARNER-LAMBERT COMPANY | 2004-12-21 | — | — | US | claimed |
| US-20040127724-A1 | 3-heteroarylalkyl substituted GABA analogs | YUEN PO-WAI (US) | 2004-07-01 | — | — | US | claimed |
| JP-2003500486-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1185524-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2000073296-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2007090661-A2 | ACTIVE SUBSTANCE COMBINATION COMPRISING AZOLYLCARBINOL COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-08-16 | — | — | WO | disclosed |
| EP-1185524-B1 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER LAMBERT CO (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6833385-B2 | Thiophene derivatives; epilepsy, faintness attacks, depression, anxiety, panic, pain; neurodegenerative, neuropathological and gastrointestinal disorders | WARNER-LAMBERT COMPANY | 2004-12-21 | — | — | US | disclosed |
| US-20040127724-A1 | 3-heteroarylalkyl substituted GABA analogs | YUEN PO-WAI (US) | 2004-07-01 | — | — | US | disclosed |
| US-6710190-B1 | ANTIEPILEPTIC, ANTIDEPRESSANT, ANXIOLYTIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANALGESIC AGENTS; NEURODEGENERATIVE AND GASTROINTESTINAL DISORDERS; IRRITABLE BOWEL SYNDROME | WARNER-LAMBERT COMPANY | 2004-03-23 | — | — | US | disclosed |
| EP-1185524-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000073296-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127724-A1 | 3-heteroarylalkyl substituted GABA analogs | GABRB3, GABRB1, GABRB2 | CYP2C19 243/4885RAB9A 852/4885CTSC 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.